Cancer-associated tumour markers CA 19-9 and CA-50 in patients with pancreatic cancer with special reference to the Lewis blood cell status.

Monoclonal antibodies 19-9 and C-50 were used to assay the cancer associated tumour antigens CA 19-9 and CA-50 in plasma from patients with confirmed pancreatic cancer, and related to the blood group and Lewis blood cell status. The plasma expressions of CA 19-9 or CA-50 were similar, including case...

Descripción completa

Detalles Bibliográficos
Autores principales: Masson, P., Pålsson, B., Andrén-Sandberg, A.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1990
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1971719/
https://www.ncbi.nlm.nih.gov/pubmed/2390470
_version_ 1782134970934886400
author Masson, P.
Pålsson, B.
Andrén-Sandberg, A.
author_facet Masson, P.
Pålsson, B.
Andrén-Sandberg, A.
author_sort Masson, P.
collection PubMed
description Monoclonal antibodies 19-9 and C-50 were used to assay the cancer associated tumour antigens CA 19-9 and CA-50 in plasma from patients with confirmed pancreatic cancer, and related to the blood group and Lewis blood cell status. The plasma expressions of CA 19-9 or CA-50 were similar, including cases where the patients had Lewis phenotype Le (a-b-). However, analyses of both the tumour antigens could be used to differentiate the presence of cancer from its absence in Le (a-b-) individuals. The findings indicate that the targets for the monoclonal antibodies 19-9 and C-50 are similar. The practical implications of these findings are discussed.
format Text
id pubmed-1971719
institution National Center for Biotechnology Information
language English
publishDate 1990
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-19717192009-09-10 Cancer-associated tumour markers CA 19-9 and CA-50 in patients with pancreatic cancer with special reference to the Lewis blood cell status. Masson, P. Pålsson, B. Andrén-Sandberg, A. Br J Cancer Research Article Monoclonal antibodies 19-9 and C-50 were used to assay the cancer associated tumour antigens CA 19-9 and CA-50 in plasma from patients with confirmed pancreatic cancer, and related to the blood group and Lewis blood cell status. The plasma expressions of CA 19-9 or CA-50 were similar, including cases where the patients had Lewis phenotype Le (a-b-). However, analyses of both the tumour antigens could be used to differentiate the presence of cancer from its absence in Le (a-b-) individuals. The findings indicate that the targets for the monoclonal antibodies 19-9 and C-50 are similar. The practical implications of these findings are discussed. Nature Publishing Group 1990-07 /pmc/articles/PMC1971719/ /pubmed/2390470 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Masson, P.
Pålsson, B.
Andrén-Sandberg, A.
Cancer-associated tumour markers CA 19-9 and CA-50 in patients with pancreatic cancer with special reference to the Lewis blood cell status.
title Cancer-associated tumour markers CA 19-9 and CA-50 in patients with pancreatic cancer with special reference to the Lewis blood cell status.
title_full Cancer-associated tumour markers CA 19-9 and CA-50 in patients with pancreatic cancer with special reference to the Lewis blood cell status.
title_fullStr Cancer-associated tumour markers CA 19-9 and CA-50 in patients with pancreatic cancer with special reference to the Lewis blood cell status.
title_full_unstemmed Cancer-associated tumour markers CA 19-9 and CA-50 in patients with pancreatic cancer with special reference to the Lewis blood cell status.
title_short Cancer-associated tumour markers CA 19-9 and CA-50 in patients with pancreatic cancer with special reference to the Lewis blood cell status.
title_sort cancer-associated tumour markers ca 19-9 and ca-50 in patients with pancreatic cancer with special reference to the lewis blood cell status.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1971719/
https://www.ncbi.nlm.nih.gov/pubmed/2390470
work_keys_str_mv AT massonp cancerassociatedtumourmarkersca199andca50inpatientswithpancreaticcancerwithspecialreferencetothelewisbloodcellstatus
AT palssonb cancerassociatedtumourmarkersca199andca50inpatientswithpancreaticcancerwithspecialreferencetothelewisbloodcellstatus
AT andrensandberga cancerassociatedtumourmarkersca199andca50inpatientswithpancreaticcancerwithspecialreferencetothelewisbloodcellstatus

Ejemplares similares